EHT301

EHT301 is an investigational gene therapy candidate being developed by Euhearing Therapeutics for the treatment of congenital monogenic hearing loss. Currently in the early research or preclinical stage, EHT301 is part of a pipeline focused on addressing genetic mutations that cause hereditary deafness. The company utilizes viral vector technology, typically adeno-associated virus (AAV), to deliver therapeutic genetic material to the sensory cells of the inner ear to restore auditory function. While EHT301 is specifically categorized for congenital monogenic hearing loss, details regarding its specific molecular target or the exact gene it aims to replace or repair have not been publicly disclosed.